



July 1, 2021

**Call for Expressions of Interest
Research Grants for Homocystinurias**

HCU Network America and HCU Network Australia established a research grant program and a Scientific Advisory Board (SAB) in 2017 to identify and advise on research priorities. Two grants have been awarded from 2018 through 2020. This third call is being initiated for Expressions of Interest (EOI) to identify a small number of potential researchers whose programs will be considered for grants and invited to submit a Grant Application.

Eligible Applicants

Eligible applicants must have a Ph.D., M.D., or equivalent degrees and currently hold a full-time position at any level (post-doctoral, research scientist, assistant/associate/full professor, etc.) at an established academic/research institution. Applicants will be considered from the United States, Australia and internationally.

Key Priorities

Key priorities for EOIs to be considered should include one of the following:

- Technologies to improve early detection of classical homocystinuria and remethylation disorders, particularly via primary markers for newborn screening
- New therapies to treat classical homocystinuria and remethylation disorders by exploring novel mechanisms to obtain proof of concept to enable progression to clinical trials

Awards are expected to be up to \$40,000 USD; however exceptional applications may be funded at a higher amount if the budget request is justified. The award requires that funds not be used for the support of institutional indirect or overhead costs. Research Grants support projects to produce proof of concept

that would facilitate more substantial funding from federal agencies, foundations or corporations.

Expression of Interest

Researchers are asked to submit an Expression of Interest (EOI) Application, not exceeding 2 pages, (single-spaced with 0.5" margins using no less than 11 point Arial fonts), and including high level description of the proposed project, potential budget range and any conflict of interests with SAB members.

EOI required details include:

- Project Title
- Principal Investigator Name
- Abstract/Summary of Project – no more than 350 words
- Hypothesis to be tested
- Significance of proposed research
- Project timeline (assuming project start May 1, 2022 and completion April 30, 2023, though extensions can be requested if appropriate)
- Project Budget (budget range is acceptable for EOI)

Please submit Expressions of Interest by August 30, 2021 to Margie McGlynn at margie@themcglynns.net. EOIs will be reviewed by the SAB, in consultation with HCU Network America and HCU Network Australia, and applicants will be notified by October 15, 2021, if they are invited to submit a Grant Application.

For additional information on the research strategy and application process for this grant program please visit:

hcunetworkamerica.org/research-grants/ or
hcunetworkaustralia.org.au/research-hcu/

Potential conflicts

An affiliation with one or more of the SAB members is considered a conflict of interest and must be stated in the covering letter. SAB members are noted below.

Scientific Advisory Board members:

Viktor Kožich, (Chair of SAB); MD, PhD, Professor of Medical Genetics, Department of Pediatrics and Inherited Metabolic Diseases, General University Hospital in Prague and Charles University-First Faculty of Medicine, Prague, Czech Republic

Matthias R. Baumgartner, Prof. Dr. med., head of Division for Metabolic Diseases and Medical Director of the Swiss Newborn Screening Program, University Children's Hospital Zurich, Zürich, Switzerland

Henk Blom, PhD, Laboratory Specialist Clinical Genetics, Center for Lysosomal and Metabolic Diseases, Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands; Professor, Biochemistry of Inherited Metabolic Disease

Kimberly Chapman, MD, Ph.D., attending physician in Genetics and Metabolism, Children's National: Assistant Professor of Pediatrics and Integrated Systems Biology, George Washington University, U.S.

Warren Kruger, Ph. D, Full professor, Cancer Biology and Epigenetics program at Fox Chase Cancer Center, Philadelphia, PA, U.S.

Andrew Morris, BM, BCh, PhD, Consultant and Senior Lecturer in Paediatric Metabolic Medicine, Willink Metabolic Unit, Manchester University Hospitals NHS Trust, UK

Patient Representatives:

Margaret McGlynn, R. Ph., Hon DSc, President of Board, HCU Network America

Tara Morrison, BA LLB, Director and Chair, HCU Network Australia